Oral administration of type I interferon modulates the course of experimental allergic neuritis

Autoimmunity

Volumn 24, Issue 3, 1996, Pages 157-165

  Vriesendorp, Francine J ^a   Flynn, Robyn E ^a   Khan, Mohammad ^a   Pappolla, Miguel A ^b   Brod, Staley A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

EAN; IRN ; IRN ; Oral feeding

Indexed keywords

GAMMA INTERFERON; INTERFERON; MYELIN;

ALLERGIC NEUROPATHY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; FEMALE; IMMUNOCYTOCHEMISTRY; INFLAMMATION; LYMPH NODE CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SPLEEN CELL;

EID: 0030454489     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.3109/08916939608995361     Document Type: Article

References (38)

1. Isaacs, A., Lindenmann, J., Virus Interference. I. The interferon. Proc. R. Soc. Lond. (Biol) 1957; 147: 258-267.
2. Johnson, H.M., Baron, S. Evaluation of effects of interferon and interferon inducers on the immune response. Pharmac. Ther. 1977; 1: 349-367.
3. Balkwill, F. R. The regulatory role of interferons in the human immune response. In: Interferons: The impact in biology of medicine, Taylor-Papadimitriou (Eds), Oxford Medical Publications, 1985; 61-80.
4. Ververken, D., Carton, H., Biliau, A. Intrathecal administration of interferon in MS patients? In: Humoral immunity in neurological disease, Karcher, D., Lowenthal, A. Strosberg, A. D. (Eds), Plenum, New York, 1979; 625-627.
5. Fog, T. Interferon treatment of multiple sclerosis patients: a pilot study. In: Search for a cause of multiple sclerosis and other chronic diseases of the CNS, Boese, A. (Ed.), Verlag Chemie, Weinheim, 1980; 491-493.
6. Montezuma-de-Carvalho, M. J. A treatment for the chronic disabilities of stable multiple sclerosis. Acta Medicotechnica 1983; 31: 155-160.
7. Panitch, H. S., Francis, G. S., Hooper, C. J. Merigan, T. C., Johnson, K. P. Serial immunological studies in multiple sclerosis patients treated systemically with human interferon alpha. Ann. Neurol. 1985; 18: 434-438.
8. Panitch, H. S. Systemic alpha-interferon in multiple sclerosis: Long term patient follow-up. Arch. Neurol. 1987; 44: 61-63.
9. Knobler, R. L. Systemic interferon therapy of multiple sclerosis: the pros. Neurology 1988; 38: 58-61.
10. Kastrukoff, L. F., Oger, J. J., Hashimoto, S. A., Sacks, S. L., Li, D. K., Palmer, M. R., Koopmans, R. A., Pethau, A. J., Berkowitz, J., Paty, D. W. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology 1990; 40: 479-486.
11. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
12. Paty, D. W., Li, D. K. B., UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993; 43: 662-667.
13. Jacobs, L, Cookfair, D., Rudick, R., Herndon, R., Salazar, A., Fisher, J., Granger, C., Simon, J., Goodkin, D., and the MS Collaborative Group. Results of a Phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis. Ann. Neural. 1994; 36(2): 259.
14. Sabatelli, M., Mignogna, T., Lippi, G., Milone, M., Di Lazarro, V., Tonali, P. Interferon-α may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psych. 1995; 58: 638-639.
15. Leger, J. M., Xavier, M., Chastang, C., Clavelou, P., Louboutin, J. P., Bouche, P., Brouet, J. C. and the IgM Associated Polyneuropathy Study Group. A randomized trial comparing alpha-interferon and intravenous immunoglobulin in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 1996; 46: A280.
16. Abreu, S. L. Suppression of experimental allergic encephalomyelitis by interferon. Immunol. Comm. 1982; 11: 1-7.
17. Abreu, S. L., Tondreau, J., Levine, D., Sowinskli, R. Inhibition of passive localized experimental allergic encephalomyelitis by interferon. Int. Arch. Allergy Appl. Immunol. 1983; 72: 30-33.
18. Schafer, T. W., Lieberman, M., Cohen, M., Came, P. Interferon administered orally: protection of neonatal mice from lethal virus challenge. Science 1972; 176: 1326-1327.
19. Cummins, J. M., Thompkins, M. S., Olsen, R. G., Tompkins, W. A., Lewis, M. G. Oral use of human alpha interferon in cats. J. Biol. Response Modifiers 1988; 7: 513-523.
20. Young, A. S., Maritim, A. C., Karuiki, D. P., Stagg, D. A., Wafula, J. M., Mutugi, J. J., Cummins, J. M., Richards, A. S., Burns, C. Low-dose oral administration of human interferon alpha can control the development of Theileria parva infection in cattle. J. Parasital. 1990; 101: 201-209.
21. Stanton, G., Hughes, T., Heard, H., Georgiades, J., Whorton, E. Modulation of a natural virus defense system by low concentrations of interferons at mucosal surfaces. J. Inf. Res. 1990; 10(S-1): S99.
22. Lecce, J. G., Cummins, J. M., Richards, A. S. Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha. J. Mol. Biotherapy 1990; 2: 211-216.
23. Brod, S. A., Burns, D. H. Suppression of relapsing experimental allergic encephalomyelitis in SJL/J mouse by oral administration of type I interferons Neurology 1994; 44: 1144-1148.
24. Brod, S. A., Scott, M., Burns, D. K., Phillips, J. T. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of Type Interferons. J. Int. Res. 1995; 15: 115-122.
25. Norton, W. T. Isolation of myelin from the nerve tissue. Methods Enzymol 1975; 31 (part A): 435.
26. 2-peptide induced experimental allergic neuritis: a model to study axonal degeneration. Acta Neuropathol. 1991; 82: 60-65.
27. Rostami, A., Gregorian, S. K., Brown, M. J., Pleasure, D.E. Induction of severeexperimental autoimmune neuritis with a synthetic peptide corresponding to the 53-78 amino acid sequence of the myelin P2 protein. J. Neuroimmunol. 1990; 30: 145-151.
28. Schmidt, B., Stoll, G., Van der Meide, P., Jung, S., Hartung, H.P. Transient cellular expression of interferon-gamma in myelin-induced and T cell line-mediated experimental autoimmune neuritis. Brain 1992; 115: 1633-1646.
29. Brod, S. A., Khan, M., Kerman, R. H., Pappolla, M. Oral administration of human or murine interferon alpha suppresses relapses and prevents adoptive transfer in EAE. J. Neuroimmunol. 1995; 58: 61-69
30. Macdonald, T. T. Immunosuppression caused by antigen feeding. II. Suppressor T cells mask Peyer's patches B cell priming to orally administered antigen. Eur. J. Immunol. 1983; 13: 138-142.
31. Mattingly, J. A. Immunologic suppression after oral administration of antigen. Cell. Immunol. 1984; 86: 45-52.
32. Santes, L. M. B., Al-Sabbagh, A., Londono, A., Weiner, H. L. Oral tolerance to MBP induces TGF-β secreting T cells in Peyer's patch. J. Immunol. 1993; 150: 115A.
33. Aune, T. M., Pierce, C. W. Activation of a suppressor T cell pathway by interferon. Proc. Natl. Acad. Sci. USA 1982; 79: 3808-3812.
34. Schnapper, H. W., Pierce, C. W., Aune, T. M. Identification and initial characterization of Con A and interferon-induced human suppressor factor: Evidence for a human equivalent of murine soluble immune response suppressor (SIRS). J. Immmunol. 1984; 132: 2429-2435.
35. Merrill, J. E., Kono, D. H., Clayton, J., Ando, D. G., Hinton, D. R. Inflammatory leukocyes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice. Prac. Natl. Acad. Sci. USA 1992; 89: 810-815.
36. Hartung, H. P., Schafer, B., Van der Meide, P. H., Fierz, W., Heininger, K., Toyka, K. V. The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the nervous system. Ann. Neurol. 1990; 27: 247-257.
37. Tsai, C. P., Pollard, J. O., Armati, P. J. Interferon-γ inhibition suppresses experimental allergic neuritis: modulation of major histocompatibility complex expression on Schwann cells in vitro. J. Neuroimmunol. 1991; 31: 133-145.
38. Arai, K., Lee, F., Miyajima, A., Miyatake, S., Arai, N., Yokata, T. Cytokines: Coordinators of immune and inflammtory responses. Annu. Rev. Biochem. 1990; 59: 783-836.